Aditum Bio is a venture capital investment firm founded in 2019 and headquartered in San Francisco, California. The firm specializes in acquiring and developing pharmaceutical assets, focusing on biotechnology and technology sectors. Aditum Bio aims to provide patients with access to medicines that may not otherwise be developed, thereby addressing unmet medical needs. As a Registered Investment Adviser, the firm operates to identify and nurture innovative therapeutic solutions.
Hubpay Technologies Ltd. operates Hubpay, a digital wallet designed for facilitating low-cost remittances and international bill payments in the United Arab Emirates. Founded in 2019 and based in Dubai, the platform aims to enhance financial inclusion in emerging markets by supporting both the remittance and mobile money sectors. Hubpay provides a user-friendly solution for individuals sending and receiving money, contributing to easier access to financial services in the region.
Via Nova Therapeutics is a biopharmaceutical company focused on discovering and developing therapeutics for acute and subacute viral infections where existing treatments are insufficient. The company’s antiviral programs, initially derived from a portfolio developed by its founders at Novartis, specifically target respiratory viruses such as influenza, adenoviruses, and rhinoviruses, as well as human polyomaviruses that can cause severe illness in immunocompromised individuals. By concentrating on the fundamental mechanisms of viral replication, Via Nova Therapeutics aims to facilitate the creation of novel antiviral therapeutics that can address a broader range of viral infections.
Versanis Bio focuses on developing therapies to address health issues prevalent among older adults, particularly obesity and its associated complications. The company's lead product, bimagrumab, is a human monoclonal antibody that targets activin type II receptors, effectively blocking the binding of ligands such as activin A and myostatin. This treatment has undergone extensive clinical evaluation, with over 1,500 participants in various controlled trials previously conducted by Novartis. Bimagrumab has shown the ability to induce significant fat loss without compromising lean muscle mass, while also improving important cardiometabolic markers such as HbA1c. Through its innovative approach, Versanis Bio aims to help overweight and obese adults achieve and maintain a healthier body composition.
Anteris Bio
Acquisition in 2020
Anteris Bio is developing a new therapy for the treatment of renal disease.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.